No Data
Mengke Pharmaceutical: Shanghai Mengke Pharmaceutical Co., Ltd. 2024 Annual Results Forecast
Shanghai Mengke Pharmaceutical Co., Ltd. 2024 Annual Results Forecast
Menk Pharmaceutical (688373.SH): Expected net loss of 0.44 billion yuan to -0.48 billion yuan in 2024.
On January 16, Gelonghui reported that Menco Pharmaceuticals (688373.SH) expects to achieve a revenue of approximately 120 million yuan to 140 million yuan in 2024, which is an increase of 29.2236 million yuan to 49.2236 million yuan compared to the same period last year, representing a year-on-year growth of 32.19% to 54.23%. It is anticipated that in 2024, the net income attributable to the parent company's owners will be approximately -480 million yuan to -440 million yuan, which is an increase in loss of 18.8755 million yuan to 58.8755 million yuan compared to the same period last year, indicating a year-on-year increase in loss of 4.
Shanghai MicuRx Pharmaceutical's Phase 1 Trial for Non-Tuberculous Mycobacteria Drug Gets China Nod
Some Shanghai MicuRx Pharmaceutical Co., Ltd. (SHSE:688373) Shareholders Look For Exit As Shares Take 25% Pounding
Mengke Pharmaceutical (688373.SH): The clinical trial application for MRX-5 has been approved.
Mengke Pharmaceutical (688373.SH) announced that the company recently received a notice from the National Medical Products Administration regarding MRX...
